Search

The article provides updates on science experiments and other socio-political activities in the U.S. A deliberation of the government whether to take or not to take underground nuclear testing is still on progress. A better way in determining whether a body anywhere in the universe is composed of matter or antimatter has been studied. The National Academy of Sciences-National Research Council is planning to evaluate thousands of drugs introduced from 1938 to 1962.

The U.S. Senator Estes Kefauver's has shocked the nation with disclosures of dubious safety standards and scandalous profits prevalent in the drug industry. Yet, when a bill to correct the drug industry's abuses reaches the floor of the U.S. Senate, it will be only a shadow of tile legislation that Kefauver wanted and that the public, according to two and a half years of testimony, badly needs. The thalidpmide drug episode compelled the U.S. President John F. Kennedy at his last news conference to announce that he would take administrative steps to prevent a recurrence. Kennedy promised that he would appoint a Consumer Counsel in the Office of the President to watch over such matters as the price and quality of drugs.

This article focuses on the assumed possibilities of the enactment of the regulatory bill named, the "Dangerous Drug Penalty Amendments of 1968" in the U.S. It was assumed that after enactment, it will impose new and heavy penalties for not only the distribution and sale but the possession for personal use of "hallucinogenic drugs and other depressant and stimulant drugs." This bill reportedly had covered a varied list of different pharmacological agents that can be affected. As there was a need for federal intervention in the business of drug abuse and control, the doubt related to this bill has created a dilemma.

The article discusses the American narcotics policy to battle against heroin addiction in the U.S. The author explained that, the said policy is formulated based on the lessons taken from the British experience. He stated that, heroin still has its place in medicine primarily as an analgesic, however, it must only be lawfully prescribed by the doctor to his patients based on his judgment. In terms of addiction, any prescription of the said drug should be reported to authorities.

Focuses on the inquiry of U.S. Senator Estes Kefauver into the prescription drug industry in the U.S. Names of profitable pharmaceutical companies; Strategies adopted by pharmaceutical companies for drug promotion; Production cost for prednisone tablets. INSET: One Drug - Two Prices.

Offers a look at the controversy over the U.S. Food and Drug Administration (FDA) recommendations regarding the safety of prescribing and administering the antihistaminic drugs meclizine and cyclizine. Cases of birth deformities seemingly associated with meclizine; Response of FDA commissioner George Larrick to studies on the teratogenic effect of meclizine on rats; Result of a study by an FDA ad hoc committee on the effect of meclizine and cyclizine; Key reasons of FDA medical director Doctor Joseph F. Saduck in endorsing the ad hoc committee's findings.

The article reports on the implications of the series of prosecutions begun by the California State Board of Pharmacy against dime-store chains Woolworth, Newberry, Kress and Grant in the Los Angeles county court for allegedly selling products which only licensed pharmacists can sell under the state pharmacy law. According to spokesmen for the chains, they are trying to fight attempts by retail druggists to establish a monopoly on the sale of every product drug listed in the U.S. Pharmacopoeia.

The article reports on the decision of the War Food Administration (WFA) to lift ban on its use in drugs and toilet preparations and authorize drugs 100 percent of their 1940 usage. The quota on glycerin for drug manufacturers has been elevated from 60 percent to 100 percent of 1940 usage. There are indications that the liberalized glycerin allocation project will last at least through early 1944. WFA stated that fats and oils allocation for soap will be heightened so that soap manufacturers can boost their production by 28 percent.

The article reports that the U.S. Federal Security Agency (FSA) has revised regulations issued by the Food and Drug Administration (FDA) related to the trademarks and labeling of habit-forming drugs and their derivatives. The FSA explained the concept of common names and labeling and their effects on the ownership of trademarks. Under the Food, Drug and Cosmetic Act, the FDA determines which drugs should include a warning about their habit-forming effects.

The article reports on Dr. Herbert L. Ley's assumption of office as commissioner of the Food and Drug Administration (FDA) in the U.S. in 1968. It mentions that Ley will replace Dr. James L. Goddard and is expected to make smoother ways of implementing the regulations on the sale of drugs and food products to consumers. It also cites that while Ley is more lenient in his approach, he is as cautious as Goddard when it comes to his duties.

This article states that the U.S. Food and Drug Administration (FDA) will begin plans to ban a group of vitamins whose efficacy is under federal investigation. It says that there are about 3,000 vitamins in the market and the FDA will remove from the market drugs proved to be ineffectual and force relabeling of these products. The FDA has yet to notify the companies that make those drugs.

This article highlights the workload problem facing the U.S. Food and Drug Administration (FDA). It cites the year-long search for the person to fill the top post at FDA only serve to emphasize the extent of the problem. This problem is expected to become more serious as the FDA is saddled by the task of implementing more drug regulations. The government is also finder hard to find the qualified persons to fill the jobs at FDA.

The article focuses on the effect of strict drug regulation by the U.S. Food and Drug Administration (FDA). According to the report of Doctors Louis Lasagna and William Wardell, pharmacologists from the University of Rochester School of Medicine and Dentistry, laws being implemented by the FDA are so strict that they inhibit drug development. As a result American patients are deprived of drugs that are used already in other countries and they have to pay more for the drugs that are available in the country. According to their study, there are 77 drugs considered by U.S. physicians as safe and effective, but are unauthorized in the country because of the FDA. Lasagna and Wardell say that a drug that is 100 percent safe at all dose level has yet to be developed.

The article discusses the proposed rule of the Federal Trade Commission (FTC) in relation to prescription drug prices in the U.S. It mentions that the rule mandating pharmacies to advertise prices for prescription drugs would benefit consumers allowing them to shop for the best bargain; thereby, allowing them to save more than 130 million dollars a year. However, such advertisements is being banned by law in 33 states and pharmacists argue that these restrictions are necessary for their business. Lewis Engman, chairman of the FTC says that the rules will override existing state laws prohibiting drug-price advertisements.

The article reports that the U.S. Federal Trade Commission (FTC) has ordered the manufacturer of Carter's Little Liver Pills to take out the word "liver" from the product name. The FTC explained that the white-coated globules are irritative laxative and have no medicinal effect on the liver. According to the article, the raw materials used in the medicine include the podophyllum resin or podophyllin which is the resin of the dried root of the mandrake or May apple.

The article reports on the increase in new drug application filed before the U.S. Food and Drug Administration because of the so-called Copeland law.

Photographs depicting two different expressions by U.S. Senator Royal Copeland are presented as his fight for new food and drug laws continues and the air safety inquiry stalled in Congress.

The article reports that drug makers and the U.S. Health, Education & Welfare Department have agreed on a policy covering the patenting of any anti-cancer drugs that may be developed with the aid of the government.

The article discusses the conflict between the U.S. Food & Drug Administration (FDA) and prescription drug makers over FDA ban on drugs it says are ineffective. The FDA reportedly announced that it will not grant hearing unless substantial evidence that the drug is effective. It indicates move by Pharmaceutical Manufacturers Association to fight FDA by directly challenging its rules in federal court and an indirect challenge through a test case. It notes that the fight is on how much proof FDA can legally demand before it can grant a hearing.

Reveals that considerable sentiment is reported to exist on the U.S. Senate Subcommittee for altering the use of medical drugs through the imposition of more bureaucratic regulation. Remarks from Dr. Jan Koch-Weser about the role of potent drugs in life-threatening diseases; Factor that makes the manufacture and distribution of drugs to American consumers one of the most complicated and expensive procedures in the world; Good news on the cost of high-quality medicine in the U.S.

The article presents a commentary on the legal issues of amphetamine sulphate use, according to George P. Larrick, Commissioner of the U.S. Food and Drug Administration. He said that the cooperation of pharmaceutical state boards and professional associations are necessary for the successful regulation of the drug. The long range safety program of the trucking industry includes the crackdown on illegal amphetamine sales.